The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues. See why ...

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report). The company’s ...

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing ...

On Tuesday, 11 March 2025, Catalyst Pharmaceuticals (NASDAQ: CPRX) presented at the Barclays 27th Annual Global Healthcare Conference. The company highlighted its strategic focus on organic growth ...

Handelsbanken Fonder AB grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 2.9% in the 4th ...

Baird raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $32 from $28 and keeps an Outperform rating on the shares. The firm ...

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Friday. Several other research ...

CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical ...